Modified Peptides Open Tight Junctions to Improve Oral Absorption of Chemotherapy Drug Doxorubicin | Research

The takeaway

Peptide derivatives of the tight junction-modulating sequence FCIGRL increased intestinal absorption of doxorubicin up to 2.38-fold in rats when combined with the stabilizer levan.

2.38× absorption increase
Pep4 combined with levan increased doxorubicin intestinal absorption 2.38-fold compared to the drug alone, with peak blood levels increasing 3.30-fold

What the researchers found

Pep4 with levan increased doxorubicin AUC by 2.38-fold (p<0.05) and Cmax by 3.30-fold (p<0.01) compared to control. Pep2 with levan/benzalkonium chloride and Pep3 with levan also significantly enhanced absorption. The peptides work by temporarily opening tight junctions between intestinal epithelial cells.

Why it matters

Many life-saving drugs, including chemotherapy agents, must be given intravenously because they can't cross the intestinal barrier. If peptide-based absorption enhancers can safely enable oral delivery of these drugs, it would dramatically improve patient quality of life, reduce healthcare costs, and potentially improve treatment adherence.

The numbers in context

Four peptide variants (Pep1-Pep4) derived from the six-mer sequence FCIGRL were tested alongside doxorubicin.

How the study worked

Animal pharmacokinetic study in rats receiving intraduodenal administration of doxorubicin with each FCIGRL-modified peptide (Pep1-Pep4) combined with stabilizers levan or benzalkonium chloride. Blood levels were measured over 240 minutes to calculate AUC and Cmax.

Who was studied

Rats receiving oral doxorubicin with peptide absorption enhancers

What this study cannot tell us

Animal study with intraduodenal delivery (bypassing stomach acid), so oral tablet performance may differ significantly. The tight junction opening is reversible, but safety of repeated daily dosing wasn't assessed. Single-dose pharmacokinetic study — chronic efficacy and toxicity unknown. Clinical translation from rats to humans requires additional studies.

How to read the evidence

Preliminary evidence from an animal pharmacokinetic study. The concept is supported by known tight junction biology, but clinical relevance requires human studies.

When this study was published

Published in 2024, building on earlier work with zonula occludens toxin-derived peptides for drug absorption enhancement.

The bigger picture

The challenge of oral drug delivery for poorly absorbed molecules affects not just chemotherapy but peptide drugs, biologics, and many other therapeutics. Tight junction-modulating peptides represent a promising approach that could eventually enable oral alternatives to injectable treatments across many disease areas.

Questions still open

Can these tight junction-modulating peptides survive stomach acid for true oral delivery, or will they need enteric coating?
Is the tight junction opening truly reversible with chronic daily dosing, and what are the long-term safety implications?

Common questions

What are tight junctions and why do they matter for drug absorption?

Tight junctions are seals between the cells lining your intestines that control what passes from the gut into the bloodstream. Most large drug molecules like doxorubicin can't squeeze through these seals. These peptides temporarily loosen the seals just enough to let the drug through, then the junctions close back up.

Could this make chemotherapy available as a pill?

Potentially, though significant hurdles remain. The study delivered drugs directly to the small intestine — a real pill would need to survive stomach acid first. Safety of repeatedly opening tight junctions also needs careful study. But the proof of concept is promising and could eventually lead to oral chemotherapy options.

Read the original research

Effect of Tight Junction-Modulating FCIGRL-Modified Peptides on the Intestinal Absorption of Doxorubicin in Rats.

Pharmaceutics, 16(5)

View on PubMed ↗Publisher’s paper ↗

Citation

Song, Keon-Hyoung. (2024). Effect of Tight Junction-Modulating FCIGRL-Modified Peptides on the Intestinal Absorption of Doxorubicin in Rats.. Pharmaceutics, 16(5). https://doi.org/10.3390/pharmaceutics16050650